|
1）Iseki K, Ikemiya Y, Kinjo K, et al. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int. 2004; 65: 1870-6
|
|
|
|
2）Foster MC, Hwang SJ, Larson MG, et al. Overweight, obesity, and the development of stage 3 CKD: The Framingham heart study. Am J Kidney Dis. 2008; 52: 39-48
|
|
|
|
|
|
3）Wang Y, Chen X, Song Y, et al. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int. 2008; 73: 19-23
|
|
|
|
|
|
4）Wahba IM, Mak RH. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol. 2007; 2: 550-62
|
|
|
|
|
|
5）Mathew AV, Okada S, Sharma K. Obesity related kidney disease. Curr Diabetes Rev. 2011; 7: 41-9
|
|
|
|
|
|
6）Wickman C, Kramer H. Obesity and kidney disease: potential mechanisms. Semin Nephrol. 2013; 33: 14-22
|
|
|
|
|
|
7）肥満症診断基準検討委員会. 肥満症診断基準 2011. 肥満研究. 2011; 17(臨時増刊号)
|
|
|
|
|
8）Weisinger JR, Kempson RL, Eldridge FL, et al. The nephritic syndrome: a complication of massive obesity. Ann Intern Med. 1974; 81: 440-7
|
|
|
|
|
|
9）Kambham N, Markowitz GS, Valeri AM, et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001; 59: 1498-509
|
|
|
|
|
|
10）Camici M, Galetta F, Abraham N, et al. Obesity-related glomerulopathy and podocyte injury: a mini review. Front Biosci. 2012; 1: 1058-70
|
|
|
|
|
|
11）Amann K, Benz K. Structural renal changes in obesity and diabetes. Semin Nephrol. 2013; 33: 23-33
|
|
|
|
|
|
12）Praga M, Hernandez E, Morales E, et al. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2001; 16: 1790-8
|
|
|
|
|
|
13）Ruster C, Wolf G. The role of the renin-angiotensin-aldosterone system in obesity-related renal disease. Semin Nephrol. 2013; 33: 44-53
|
|
|
|
|
|
14）Deji N, Kume S, Araki S, et al. Structural and functional changes in the kidneys of high-fat diet-induced obese mice. Am J Physiol Renal. 2009; 296: F118-26
|
|
|
|
|
|
15）Santini E, Lupi R, Baldi S, et al. Effects of different LDL particles on inflammatory molecules in human mesangial cells. Diabetologia. 2008; 51: 2117-25
|
|
|
|
|
|
16）Zoccali C, Mallamaci F, Tripepi G, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol. 2002; 13: 134-41
|
|
|
|
|
|
17）Jalovaara K, Santaniemi M, Timonen M, et al. Low serum adiponectin level as a predictor of impaired glucose regulation and type2 diabetes mellitus in a middle-aged Finnish population. Metabolism. 2008; 57: 1130-4
|
|
|
|
|
|
18）Ohashi K, Iwatani H, Kihara S, et al. Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice. Arterioscler Thromb Vasc Biol. 2007; 27: 1910-7
|
|
|
|
|
|
19）Cui W, Maimaitiyiming H, Qi X, et al. Thrombospondin1 mediates renal dysfunction in a mouse model of high fat diet-induced obesity. Am J Physiol Renal Physiol. 2013: 305: F871-80
|
|
|
|
|
|
20）Tang J, Yan H, Zhuang S. Inflammation and oxidative stress in obesity-related glomerulopathy. Int J Nephrol. 2012; 2012: 608397
|
|
|
|
|
|
21）Wu Y, Liu Z, Xiang Z, et al. Obesity-related glomerulopathy: insights from gene expression profiles of the glomeruli derived from renal biopsy samples. Endocrinology. 2006; 147: 44-50
|
|
|
|
|
|
22）Gotoh K, Inoue M, Masaki T, et al. Obesity-related chronic kidney disease is associated with spleen-derived IL-10. Nephrol Dial Transplant. 2013; 28: 1120-30
|
|
|
|
|
|
23）Engeli S, Feldpausch M, Gorzelniak K, et al. Association between adiponectin and mediators of inflammation in obese woman. Diabetes. 2003; 52: 942-7
|
|
|
|
|
|
24）Nagase M. Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome. Clin Exp Nephrol. 2010; 14: 303-14
|
|
|
|
|
|
25）Jauregui A, Mintz DH, Mundel P, et al. Role of altered insulin signaling pathways in the pathogenesis of podocyte malfunction and microalbuminuria. Curr Opin Nephrol Hypertens. 2009; 18: 539-45
|
|
|
|
|
|
26）Praga M. Synergy of low nephron number and obesity: a new focus on hyperfiltration nephropathy. Nephrol Dial Transplant. 2005; 20: 2594-7
|
|
|
|
|
|
27）Tsuboi N, Utsunomiya Y, Kanzaki G, et al. Low glomerular density with glomerulomegaly in obesity-related glomerulopathy. Clin J Am Soc Nephrol. 2012; 7: 735-41
|
|
|
|
|
|
28）Ingelfinger JR, Schnaper HW. Renal endowment: Developmental origins of adult disease. J Am Soc Nephrol. 2005; 16: 2533-6
|
|
|
|
|
|
29）Schreuder MF, Nauta J. Prenatal programming of nephron number and blood pressure. Kidney Int. 2007; 72: 265-8
|
|
|
|
|
|
30）Hughson M, Farris AB III, Douglas-Denton R, et al. Glomerular number and size in autopsy kidneys: the relationship to birth weight. Kidney Int. 2003; 63: 2113-22
|
|
|
|
|
|
31）Griffin KA, Kramer H, Bidani AK. Adverse renal consequences of obesity. Am J Physiol Renal Physiol. 2008; 294: F685-96
|
|
|
|
|
|
32）Silverwood RJ, Pierce M, Hardy R, et al. Low birth weight, later renal function, and the roles of adulthood blood pressure, diabetes, and obesity in a British birth cohort. Kidney Int. 2013; (doi: 10.1038/ki.2013.223)
|
|
|
|
|
|
33）Afshinnia F, Wilt TJ, Duval S, et al. Weight loss and proteinuria: systemic review of clinical trials and comparative cohorts. Nephrol Dial Transplant. 2010; 25: 1173-83
|
|
|
|
|
|
34）Ix JH, Sharma K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol. 2010; 21: 406-12
|
|
|
|
|
|
35）Weber MA, Jamerson K, Bakris GL, et al. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomized controlled trial. Lancet. 2013; 381: 537-45
|
|
|
|
|